Exciting New Targets in Lung Cancer Therapy: ALK, IGF-1R, HDAC, and Hh
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Oncology
Link
http://link.springer.com/content/pdf/10.1007/s11864-010-0120-6.pdf
Reference58 articles.
1. American Cancer Society: Cancer Facts & Figures 2009. Atlanta: American Cancer Society; 2009
2. Morris SW, Naeve C, Mathew P, et al.: ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin’s lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 1997, 14(18):2175–2188.
3. Iwahara T, Fujimoto J, Wen D, et al.: Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 1997, 14(4):439–449.
4. Morris SW, Kirstein MN, Valentine MB, et al.: Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 1994, 263(5151):1281–1284.
5. Soda M, Choi YL, Enomoto M, et al.: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448(7153):561–566.
Cited by 48 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. IC Regimen: Delaying Resistance to Lorlatinib in ALK Driven Cancers by Adding Repurposed Itraconazole and Cilostazol;Cells;2024-07-10
2. Discovery of novel anaplastic lymphoma kinase (ALK) and histone deacetylase (HDAC) dual inhibitors exhibiting antiproliferative activity against non-small cell lung cancer;Journal of Enzyme Inhibition and Medicinal Chemistry;2024-03-11
3. Insulin resistance in NSCLC: unraveling the link between development, diagnosis, and treatment;Frontiers in Endocrinology;2024-02-20
4. Costs and Causes of Oncology Drug Attrition With the Example of Insulin-Like Growth Factor-1 Receptor Inhibitors;JAMA Network Open;2023-07-28
5. Small cell lung cancer: an overview of the targets;Brazilian Journal of Pharmaceutical Sciences;2022
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3